CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest

BACKGROUND: Cell cycle dysregulation is common in human malignancies, and CDK4/6 inhibitors targeting cell cycle have potential antitumor activity. SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. However, the role of SHR6390 in esophageal squamous cell carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiayuan, Li, Qingqing, Yuan, Jiajia, Wang, Jingyuan, Chen, Zuhua, Liu, Zhentao, Li, Zhongwu, Lai, Yumei, Gao, Jing, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457542/
https://www.ncbi.nlm.nih.gov/pubmed/28578693
http://dx.doi.org/10.1186/s12967-017-1231-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457542/
https://www.ncbi.nlm.nih.gov/pubmed/28578693
http://dx.doi.org/10.1186/s12967-017-1231-7

Ejemplares similares